Dupilumab is a human monoclonal antibody that inhibits overactive signaling of IL-4 and IL-13, which are thought to be the primary drivers of the ongoing underlying inflammation that occurs in atopic dermatitis, among other disorders. SUGGESTED for you Dupilumab will be available in a premixed sy...
Purpose of review: The IL-4/13 antagonist dupilumab was approved in 2017 as the first biologic for atopic dermatitis. Here, we comprehensively review compelling new data regarding dupilumab published following the approval. Recent findings: Daily clinical practice reports of dupilumab in atopic ...
“There really has not been an approved, systemic treatment for moderate to severe atopic dermatitis…dupilumab certainly would be a very revolutionary treatment.” "Not only has it shown efficacy in atopic dermatitis, but dupilumab also has shown efficacy in related atopic dermatitis conditions such ...
2 With the latest approval, dupilumab now boasts more than a dozen approvals from the FDA, including indications as either an add-on or primary therapy for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, or eosinophilic esophagitis. The FDA decision followed ...
but the FDA requested additional data from the pivotal BOREAS and NOTUS studies.2With the latest approval, dupilumab now boasts more than a dozen approvals from the FDA, including indications as either an add-on or primary therapy for atopic dermatitis, asthma, chronic rhinosinusitis with nasal ...
Dupilumab: First Global Approval. PMID: 28547386 Use of Dupilumab in Glucocorticoid-Dependent Asthma. PMID: 35922047 Dupilumab for the treatment of adolescents with atopic dermatitis. PMID: 32720530 Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Resul...
Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and COPD in differe...
FDA Drug Approvals Q3 2024 GW Teledermatology Model Expands to Four Underserved Areas The Metaverse Is the Dermatologist's Ally Recommended Reading Diseases & Conditions Atopic Dermatitis in Emergency Medicine Diseases & Conditions Pediatric Atopic Dermatitis Diseases & Conditions Atopic Dermatitis ...
In March 2017 dupilumab received its first global approval, in the USA, for use in the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab is in pre...
improved quality of life and showed statistically significant and clinically meaningful improvements in lung function. Following the approvals in atopic dermatitis and asthma, and recently announced positive Phase 3 results in chronic rhinosinusitis with nasal polyps, we are committed to advancing our broa...